Literature DB >> 6228947

The effect of low doses of d-amphetamine on drug-induced hyperactivity in the mouse.

J S Hussey, N D Vincent, J A Davies.   

Abstract

The effect of low doses (7.5-250 micrograms/kg) of d-amphetamine was studied on benztropine- or gamma-butyrolactone-induced hyperactivity in the mouse. Amphetamine 30-125 micrograms/kg significantly attenuated the drug-induced hyperactivity. This effect was antagonised by both cinanserin and p-chlorophenylalanine. The results suggest that low doses of d-amphetamine release 5-hydroxytryptamine, which in turn has an inhibitory effect on locomotor activity. This effect was masked at higher doses of d-amphetamine due to a release of dopamine.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6228947     DOI： 10.1007/bf00427571

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN： 0033-3158            Impact factor:   4.530


  14 in total

1.  Effects of the d- and l-isomers of amphetamine on uptake, release and catabolism of norepinephrine, dopamine and 5-hydroxytryptamine in several regions of rat brain.

Authors:  J C Holmes; C O Rutledge
Journal:  Biochem Pharmacol       Date:  1976-02-15       Impact factor: 5.858

2.  Dopaminergic neurons: similar biochemical and histochemical effects of gamma-hydroxybutyrate and acute lesions of the nigro-neostriatal pathway.

Authors:  J R Walters; R H Roth; G K Aghajanian
Journal:  J Pharmacol Exp Ther       Date:  1973-09       Impact factor: 4.030

3.  Attenuation of hyperactivity in the spontaneously hypertensive rat by amphetamine.

Authors:  M M Myers; R E Musty; E D Hendley
Journal:  Behav Neural Biol       Date:  1982-01

4.  The effect of gamma-butyrolactone on locomotor activity in the rat.

Authors:  J A Davies
Journal:  Psychopharmacology (Berl)       Date:  1978-12-15       Impact factor: 4.530

5.  The effect of sodium -hydroxybutyrate on the metabolism of dopamine in the brain.

Authors:  D A Hutchins; K S Rayevsky; D F Sharman
Journal:  Br J Pharmacol       Date:  1972-11       Impact factor: 8.739

6.  Amphetamine and apomorphine responses in the rat following 6-OHDA lesions of the nucleus accumbens septi and corpus striatum.

Authors:  P H Kelly; P W Seviour; S D Iversen
Journal:  Brain Res       Date:  1975-09-05       Impact factor: 3.252

7.  Possible involvement of serotonergic neurons in the reduction of locomotor hyperactivity caused by amphetamine in neonatal rats depleted of brain dopamine.

Authors:  T G Heffner; L S Seiden
Journal:  Brain Res       Date:  1982-07-22       Impact factor: 3.252

8.  Behavioral studies following lesions of the mesolimbic and mesostriatal serotonergic pathways.

Authors:  M A Geyer; A Puerto; D B Menkes; D S Segal; A J Mandell
Journal:  Brain Res       Date:  1976-04-23       Impact factor: 3.252

9.  A role for 5-hydroxytryptamine in the GABA-mimetic potentiation of alpha-flupenthixol-induced catalepsy in the rat.

Authors:  J A Davies; J Williams
Journal:  Br J Pharmacol       Date:  1983-01       Impact factor: 8.739

10.  The role of presynaptic receptors in the release and synthesis of 3H-dopamine by slices of rat striatum.

Authors:  T C Westfall; M J Besson; M F Giorguieff; J Glowinski
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1976       Impact factor: 3.000
View more
  3 in total

Review 1.  Pharmacological models of ADHD.

Authors:  R M Kostrzewa; J P Kostrzewa; R A Kostrzewa; P Nowak; R Brus
Journal:  J Neural Transm (Vienna)       Date:  2007-11-12       Impact factor: 3.575

2.  5-Hydroxytryptamine involvement in the locomotor activity suppressant effects of amphetamine in the mouse.

Authors:  A J Bradbury; B Costall; R J Naylor; E S Onaivi
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

3.  Serotoninergics attenuate hyperlocomotor activity in rats. Potential new therapeutic strategy for hyperactivity.

Authors:  Ryszard Brus; Przemyslaw Nowak; Ryszard Szkilnik; Urszula Mikolajun; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.